Truist analyst Srikripa Devarakonda raised the firm’s price target on Incyte (INCY) to $103 from $93 and keeps a Hold rating on the shares. The firm is updating its model to reflect credit to mCALR in ET – Essential Thrombocythemia – and MF – Myelofibrosis – given supporting proof of concept data, recent ET FDA breakthrough therapy designation and anticipated initiation of ET pivotal trial in 2026, the analyst tells investors in a research note.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INCY:
- Incyte announces approval of Zynyz combination in Japan
- Incyte Steps Into Late-Stage Colorectal Cancer Race With New Phase 3 Trial of INCA33890
- Incyte announces European Commission approval of second indication for Minjuvi
- Incyte’s mCALR Monoclonal Antibody Shows Promise Amid Complex Myelofibrosis and Thrombocythemia Treatment Landscape
- Incyte’s Latest Study Completion: A Step Forward in Drug Interaction Insights